1. Home
  2. FUBO vs DVAX Comparison

FUBO vs DVAX Comparison

Compare FUBO & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo fuboTV Inc.

FUBO

fuboTV Inc.

HOLD

Current Price

$2.71

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.91

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUBO
DVAX
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
FUBO
DVAX
Price
$2.71
$10.91
Analyst Decision
Buy
Buy
Analyst Count
4
4
Target Price
$5.35
$26.50
AVG Volume (30 Days)
10.3M
1.6M
Earning Date
11-03-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$1,616,726,000.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
$5.99
$15.85
P/E Ratio
$7.99
N/A
Revenue Growth
1.70
26.73
52 Week Low
$1.21
$9.20
52 Week High
$6.45
$14.63

Technical Indicators

Market Signals
Indicator
FUBO
DVAX
Relative Strength Index (RSI) 35.57 51.29
Support Level $2.55 $10.63
Resistance Level $2.76 $11.02
Average True Range (ATR) 0.11 0.23
MACD 0.01 -0.04
Stochastic Oscillator 37.80 50.90

Price Performance

Historical Comparison
FUBO
DVAX

About FUBO fuboTV Inc.

FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: